Intra-Cellular roars back on success in bipolar depression

Shares of Intra-Cellular Therapeutics popped Wednesday as new clinical data reinforced the view of investment banks that the New York-based biotech has a blockbuster psychiatry drug on its hands.
The results came from a large study that tested Intra-Cellular's drug, known as lumateperone, in hundreds of patients with bipolar disorder who have accompanying major depressive episodes.